Metabolic10 mgGLP-3 Retatrutide
GLP-1/GIP/Glucagon Triple Receptor Agonist • LY3437943
Experimental triple-hormone agonist for metabolic research.
About this peptide
Retatrutide is the most powerful metabolic peptide of its generation — a single molecule that activates the GLP-1, GIP and glucagon receptors simultaneously to reshape appetite, body composition and energy expenditure.
Retatrutide (LY3437943) engages three of the body's most decisive metabolic switches at once. GLP-1 activation restores satiety and slows gastric emptying, GIP amplifies insulin efficiency, and glucagon activation raises resting energy expenditure — a combination no earlier peptide has achieved.
The result is rapid, sustained fat loss with preserved lean mass, sharper glycaemic control and dramatic improvements in lipid profile, blood pressure and hepatic fat. Users experience quiet appetite, effortless portion control and a steady climb in daily energy.
Retatrutide sits at the frontier of metabolic medicine, delivering outcomes that eclipse first-generation GLP-1 agonists across every measured endpoint.
Key highlights
Simultaneous GLP-1, GIP and glucagon activation for maximal metabolic effect.
Consistent, dose-dependent reduction in total and visceral fat mass.
Glucagon signalling raises basal metabolic rate rather than suppressing it.
Improves fasting glucose, HbA1c and insulin sensitivity.
Research applications
- Powerful, sustained reduction in body weight and visceral fat
- Deep appetite regulation without cravings or fatigue
- Improved insulin sensitivity and fasting glucose
- Reduced hepatic fat and healthier lipid profile
- Increased resting energy expenditure
- Preserves lean muscle mass during fat loss
Specifications
- Class
- GLP-1 / GIP / Glucagon triagonist
- Presentation
- 10 mg lyophilised vial
- Purity
- Batch tested · HPLC verified
- Storage
- 2–8 °C, protect from light
For research use only. Not intended for human or veterinary therapeutic use.
